World’s first-of-a-kind kit can detect up to 50 inborn disorders
18th January, 2016 – Trivitron Healthcare, the largest and most trusted company in Medical Technology, is set to launch its patented NeoMass AAAC Kit (CE Approved) for expanded panel of newborn screening, during the Arab Health 2016, the Middle East region’s largest healthcare industry event, which will run from January 25th to 28th, 2016 at the Dubai International Convention and Exhibition Centre (DICEC). Released through its Finland subsidiary, Labsystems Diagnostics, the kit is the first-of-its-kind in the global market as it can detect up to 50 disorders that a newborn baby might be born with or without any immediate symptoms or visible manifestations–making it the broadest available panel of biomarkers. The launch of NeoMass AAAC Kit will make Trivitron a complete solution provider for NBS with Modular Systems, Automated Systems & Kits for core panel screening and Tandem MS/MS and NeoMass AAAC kit for expanded panel screening. Trivitron’s Labsystems Diagnostics Oy, Finland is the world’s no. 2 brand in the newborn screening product segment.
Trivitron aims to create awareness among the target audience about newborn screening and the need to make it mandatory. The testing process involves pricking the heel of a newborn baby to collect a few drops of blood on a filter paper within 72 hours of birth and test for detection of life threatening disorders. Using NeoMass AAAC kit would lead to screening of inborn metabolic disorders based on a technology called ‘tandem mass spectrometry,’ which allows fast and accurate determination of metabolic disorders.
The recently patented methodology makes it possible to detect deficiencies of all the six enzymes involved in the urea cycle metabolic pathway. The urea cycle is a metabolic pathway occurring in the liver and kidney and aberrant functions of the urea cycle enzymes lead to the buildup of ammonia, a product of protein metabolism. If not treated, the outcome is very serious with symptoms ranging from vomiting and increasing lethargy to respiratory distress and even coma and death. Additionally NeoMass AAAC enables an easy and reliable detection of type I tyrosinemia, a serious disease causing dermatologic and neuro developmental problems due to accumulation of tyrosine within the liver and kidney.
Dr. GSK Velu, Chairman and Managing Director, Trivitron Group of Companies, said, “Trivitron Healthcare’s Labsystems Diagnostics is one of the largest provider for newborn screening solutions in the world and our new patented NeoMass AAAC kit is the first kit in the world to detect up to 50 disorders. We, at Trivitron Healthcare, are privileged to announce the International launch of NeoMass AAAC Kit at Arab Healthcare 2016.”